Turtle Cameron's Form 4 filing
Spyre Therapeutics, Inc. (SYRE) · filed Mar 3, 2026
- Accession no.
- 0001636282-26-000026
- Filed
- Mar 3, 2026
- Trade date
- Mar 2, 2026
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $632.9K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Turtle CameronCIK 0001758363 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 2, 2026 | Common Stock | SSaleDisposed | −5,900 | $41.73 | −$246,207 | 651,640 | Direct | |
| Mar 2, 2026 | Common Stock | SSaleDisposed | −9,100 | $42.49 | −$386,659 | 642,540 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.